Granisetron PCD Pharma Franchise Company
Cafoli Lifecare offers 3 Granisetron formulations across injections, tablets and syrup for PCD pharma franchise and third-party manufacturing. Every batch is produced in WHO-GMP certified facilities, giving distributors a reliable antiemetic option for oncology and surgical care.
What is Granisetron?
Granisetron is a selective 5-HT3 (serotonin) receptor antagonist. By blocking serotonin at receptors in the gut and central nervous system, it prevents the nausea and vomiting triggered by chemotherapy, radiotherapy and surgery. See MedlinePlus for detailed drug information.
Therapeutic Applications
Granisetron is used to prevent chemotherapy-induced and radiotherapy-induced nausea and vomiting (CINV/RINV) and post-operative nausea and vomiting (PONV). It is prescribed chiefly by oncologists, anaesthetists, surgeons and gastroenterologists.
Why Granisetron is a High-Potential Molecule for Distributors
India’s expanding oncology and day-care surgery infrastructure drives steady demand for potent antiemetics. Granisetron is a first-line agent in these settings, and its injectable format supports hospital-supply and tender business while the oral and syrup forms serve follow-up outpatient care — giving franchise partners both institutional and retail revenue streams.
Why Choose Cafoli Lifecare
Cafoli Lifecare supports partners with monopoly PCD rights, WHO-GMP manufacturing, DCGI-approved formulations, complete promotional inputs and a network of 1000+ franchise partners across India.
References
- MedlinePlus – Granisetron
- PubChem – Granisetron
- PubMed – Granisetron research
Our formulations of Granisetron find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: